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Summary
 
Synaptotagmins (Syts) I and II are believed to act as Ca
 
2
 
1
 
 sensors in the control of neurotrans-
mission. Here we demonstrate that mast cells express Syt II in their lysosomal fraction. We
further show that activation of mast cells by either aggregation of Fc
 
e
 
RI or by Ca
 
2
 
1
 
 ionophores
results in exocytosis of lysosomes, in addition to the well documented exocytosis of their secre-
tory granules. Syt II directly regulates lysosomal exocytosis, whereby overexpression of Syt II
inhibited Ca
 
2
 
1
 
-triggered release of the lysosomal processed form of cathepsin D, whereas sup-
pression of Syt II expression markedly potentiated this release. These findings provide evidence
for a novel function of Syt II in negatively regulating Ca
 
2
 
1
 
-triggered exocytosis of lysosomes,
and suggest that Syt II–regulated secretion from lysosomes may play an important role in mast
cell biology.
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M
 
ast cells are specialized secretory cells that belong to
the immune system. Through triggered exocytosis
of their secretory granules (SGs),
 
1
 
 mast cells release biologi-
cally active substances, including vasoactive amines, pro-
teases, and preformed cytokines. In addition, after their ac-
tivation, mast cells produce and release arachidonic acid
metabolites such as leukotrienes, prostaglandins, and multi-
functional cytokines. Together, these mediators play cen-
tral roles in both the immediate and late phase inflamma-
tory reactions (1, 2). Although their physiological role in
the body is less clear, mast cells importantly contribute to
host defense against bacterial and parasite infections (3–8) as
well as to cellular immune responses through their ability
to present antigens and trigger antigen-specific T cell pro-
liferation (9, 10).
Previous studies of exocytosis in mast cells indicate that
the final trigger to exocytosis involves a late acting GTP-
binding protein (11, 12) and
 
 
 
Ca
 
2
 
1
 
 (13, 14). The molecular
identity of the mast cell exocytic Ca
 
2
 
1
 
 sensor remains ob-
scure. In the synapse, this role has been ascribed to synap-
totagmins (Syts) I and II, abundant Ca
 
2
 
1
 
 and phospholipid
binding proteins localized on synaptic vesicles (SVs) (15–
20). Binding of Ca
 
2
 
1
 
 to Syt results in a conformational (21)
or electrostatic (22) change that, by an as yet unresolved
mechanism, allows exocytosis to occur. The finding that
Syt I and II belong to a larger family of ubiquitously ex-
pressed proteins suggests that Syt isoforms may function as
general Ca
 
2
 
1
 
 sensors (23, 24). This hypothesis is supported
by the recent demonstration of a role for a Syt isoform in
controlling insulin secretion (25, 26).
We have recently reported that expression of Syt I in
RBL-2H3 cells (a mucosal mast cell line) resulted in prom-
inent potentiation and acceleration of Ca
 
2
 
1
 
-dependent
exocytosis (27). Therefore, in this study we decided to
identify the Syt isoform which is endogenously expressed
in RBL cells, and explore its role in controlling exocytosis.
We found that rat basophilic leukemia (RBL) cells endoge-
nously express the Syt isoforms II, III, and V. The role of
Syt II, the most abundant isoform in RBL cells, was inves-
tigated.
 
Materials and Methods
 
Antibodies.
 
Antibodies used included rabbit polyclonal serum
directed against the cytoplasmic domain of Syt I (a gift from Dr.
T.C. Sudhof, Howard Hughes Medical Institute, University of
Texas Southwestern Medical School, Dallas, TX), mAbs directed
against the NH
 
2
 
-terminal region of Syt II (a gift from Dr. M. Ta-
 
1
 
Abbreviations used in this paper:
 
 BMMC, bone marrow-derived mast cell;
RBL, rat basophilic leukemia; RPMC, rat peritoneal mast cell; SG, secre-
tory granule; SV, synaptic vesicle; Syt, synaptotagmin; TPA, 12-O-tet-
radecanoylphorbol-13-acetate. 
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kahashi, Mitsubishi-Kasei Institute of Life Sciences, Tokyo, Ja-
pan), and polyclonal antibodies against cathepsin D (Calbiochem).
 
Isolation and Growth of Mast Cells.
 
Bone marrow-derived mast
cells (BMMCs) were obtained as previously described (28). In
brief, femoral bone marrow cells from 6-wk-old BALB/c mice
were cultured in 50% WEHI-3 cells conditioned medium. Cul-
ture medium was changed weekly, and nonadhering cells were
used for further growth. After 3 wk, at least 99% of the cells were
identified as mast cells by toluidine blue staining. Rat peritoneal
mast cells (RPMCs) were obtained from Wistar rats by peritoneal
lavage, and purified as previously described (29). In brief, a sus-
pension of washed peritoneal cells was layered over a cushion of
30% Ficoll 400 (Pharmacia Biotech Inc.) in buffered saline and
0.1% BSA and centrifuged at 150 
 
g
 
 for 15 min. The purity of
mast cells recovered from the bottom of the tube was 
 
.
 
90%, as
assessed by toluidine blue staining. RBL-2H3 cells (hereafter
termed RBL cells) were maintained in adherent cultures in
DMEM supplemented with 10% FCS in a humidified atmosphere
of 6% CO
 
2
 
 at 37
 
8
 
C.
 
Reverse Transcription and PCR Amplification of Syt cDNA Frag-
ments.
 
RNA was isolated from trypsinized RBL cells collected
by centrifugation at 400 
 
g
 
 for 5 min, and from brains that were
rapidly excised from 150–200-g Sprague-Dawley rats killed by
CO
 
2
 
 suffocation and then exsanguinated. Total RNA was iso-
lated on a guanidine thiocyanate/CsCl gradient, extracted twice
with phenol/chloroform, and then ethanol precipitated. The
RNA was dissolved in 0.1% diethyl pyrocarbonate–treated water,
quantified by measuring absorbance at 260 nm, evaluated for
degradation by agarose-formaldehyde gel electrophoresis, and
frozen until used. The mRNA was isolated from total RNA by
oligo-dT cellulose chromatography [Poly(A)Pure; Ambion], and
2 
 
m
 
g was reverse transcribed by 125 U of Moloney’s murine leu-
kemia virus–reverse transcriptase (New England BioLabs) in a 50 
 
m
 
l
reaction containing 2.5 
 
m
 
g each of (dT)
 
18
 
 and random octamers,
1 mM of each dNTP, and 40 U of RNAsin (Promega) at 37
 
8
 
C
for 30 min, 42
 
8
 
C for 30 min, and 50
 
8
 
C for 15 min. The first
round of nested PCR was performed with 1 
 
m
 
l of AmpliTaq
(Perkin-Elmer Cetus) in 100 
 
m
 
l reaction buffer supplemented
with 1.5 mM MgCl
 
2
 
, 10% (vol/vol) DMSO, 1 
 
m
 
M of each
primer, 50 
 
m
 
M of each dNTP, and 1 
 
m
 
l of the reverse transcrip-
tion reaction as template. The four primers correspond to RNA
sequences encoding portions of Syt proteins schematized in Fig.
1 A, and their sequences were: A,
 
 
 
TCWGACCCYTAYGT-
CAARRTCT; B,
 
 
 
AGACCCARGTGCACMGGAAGAC; C,
SYCYTTSACRTAGGGRTCTGA; D,
 
 
 
GGGGTTSAGSGT-
GTTCTTCTT. For the first round of PCR, six cycles of 94
 
8
 
C
for 1 min ramping to 49
 
8
 
C in 3 min, 49
 
8
 
C for 1 min, 72
 
8
 
C for
1 min were followed by 24 cycles of 94
 
8
 
C for 1 min, 65
 
8
 
C for
1 min, 72
 
8
 
C for 1 min, with a final extension at 72
 
8
 
C for 6 min. 1 
 
m
 
l
of the PCR product obtained with RBL cell cDNA and the A
and D primers was used for template in a second round of PCR
identical to the first except that the initial six cycles with low an-
nealing temperature were not included. The product of the sec-
ond reaction using the B and C primers was purified by agarose
gel electrophoresis, then ligated into the pCR-II vector (Invitro-
gen). DH5
 
a
 
 cells were transformed with the ligation mixture and
colonies were selected for sequencing.
 
Ribonuclease Protection Assay.
 
Vectors containing the PCR-
cloned Syt fragments were linearized with NotI for SP6-directed
synthesis of riboprobes or with BamHI for T7-directed cRNA
synthesis. cRNA hybridization controls were generated in a 50 
 
m
 
l
reaction containing 3 
 
m
 
g of template DNA, 1.6 U/
 
m
 
l RNAsin,
10 mM dithiothreitol (DTT), 0.1 mg/ml BSA, 1 mM of each
NTP, 2.5 
 
m
 
M [
 
3
 
H]UTP (45 Ci/mmol; Amersham), and 100 U
T7 RNA polymerase (New England Biolabs) in the manufac-
turer’s buffer. Reactions were incubated for 4 h at 37
 
8
 
C, 10 U
DNAse I was added, and the incubation was continued for another
20 min, and then cRNA was purified on a Nick-Spin column
(Ambion). Riboprobes were transcribed in a 20 
 
m
 
l reaction using
1 
 
m
 
g of template DNA, 25 
 
m
 
M 
 
a
 
-[
 
32
 
P]CTP (800 Ci/mmol; Am-
ersham), 2 U/
 
m
 
l RNasin, 10 mM DTT, 0.1 mg/ml BSA, 0.5 mM
each of other NTPs, and 10 U SP6 RNA polymerase (New En-
gland Biolabs) in the manufacturer’s buffer for 1 h at 40
 
8
 
C. After
treatment with 5 U of DNAse I, full-length transcripts were iso-
lated by gel purification in 5% acrylamide/8 M urea gels. RNase
protection assays were performed using the RPA II kit (Ambion).
Cognate cRNA (0.1 pmol) and yeast RNA were used as positive
and negative controls. Each experiment contained 1 pmol ribo-
probe and varying amounts of RBL cell RNA supplemented
with yeast RNA to complete a total of 40 
 
m
 
g RNA. Hybridiza-
tion was carried out overnight at 45
 
8
 
C. Protected probes were
electrophoresed through 5% acrylamide/8 M urea gels and visu-
alized by autoradiography.
 
Preparation of Mast Cell and Brain Lysates.
 
Mast cells (10
 
6
 
) de-
rived from different sources (RPMCs, BMMCs, and RBL-2H3)
were washed in PBS and resuspended in 30 
 
m
 
l of lysis buffer (50 mM
Hepes, pH 7.4, 150 mM NaCl, 10 mM EDTA, 2 mM EGTA,
1% Triton X-100, 0.1% SDS, 50 mM NaF, 10 mM NaPPi, 2 mM
NaVO
 
4
 
, 1 mM PMSF, and 10 
 
m
 
g/ml leupeptin) and centrifuged
at 12,000 
 
g
 
 for 15 min at 4
 
8
 
C. The cleared supernatants were
mixed with 5
 
3
 
 Laemmli sample buffer to a final concentration of
1
 
3
 
, boiled for 5 min, and subjected to SDS-PAGE and immuno-
blotting. For the preparation of brain homogenate, whole brain
from a Wistar rat was homogenized in PBS at 4
 
8
 
C using a Poly-
tron (Kinematica, GmbH, Switzerland; 20 s, setting 7). Aliquots
(5–10 
 
m
 
g protein) were mixed with 5
 
3
 
 Laemmli sample buffer,
boiled for 5 min, and subjected to SDS-PAGE and immunoblot-
ting.
 
Subcellular Fractionation of RBL Cells.
 
RBL cells (7 
 
3
 
 10
 
7
 
) were
washed with PBS and suspended in homogenization buffer (0.25 M
sucrose, 1 mM MgCl
 
2
 
, 800 U/ml DNase I [Sigma Chemical
Co.], 10 mM Hepes, pH 7.4, 1 mM PMSF, and a cocktail of
protease inhibitors [Boehringer Mannheim, Germany]). Cells
were then disrupted by 3 cycles of freezing and thawing followed
by 20 passages through a 21-gauge needle. Unbroken cells and
nuclei were removed by sequential filtering through 5- and
2-
 
m
 
m filters (Poretics Co.). The final filtrate was then centrifuged
for 10 min at 500 
 
g
 
 and the supernatant loaded onto a continu-
ous, 0.45–2.0 M sucrose gradient (10 ml), which was layered
over a 0.3 ml cushion of 70% (wt/wt) sucrose and centrifuged for
18 h at 100,000 
 
g
 
. Histamine was assayed fluorimetrically after
condensation in alkaline medium with 
 
o
 
-phthalaldehyde (30).
LDH activity was assayed using LDH reagent according to the
manufacturer’s instructions (Merck Diagnostica, Germany).
 
Secretion from RBL Cells.
 
RBL-2H3 cells were seeded in
24-well plates at 2 
 
3
 
 10
 
5
 
 cells per well and incubated overnight
in a humidified incubator at 37
 
8
 
C. The cells were then washed
three times in Tyrode’s buffer (10 mM Hepes, pH 7.4, 130 mM
NaCl, 5 mM KCl, 1.4 mM CaCl
 
2
 
, 1 mM MgCl
 
2
 
, 5.6 mM glu-
cose, and 0.1% BSA) and stimulated in the same buffer with the
indicated concentrations of the calcium ionophore A23187 and
the phorbol ester 12-O-tetradecanoyl-13-acetate (TPA; Calbio-
chem). Secretion was allowed to proceed for 30 min at 37
 
8
 
C. Al-
iquots from the supernatants were taken for measurements of re-
leased 
 
b
 
-hexosaminidase activity. Cells in control wells were
lysed by addition of 0.1% Triton X-100 to determine the total 
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enzyme content. For Fc
 
e
 
RI induced secretion, cells were pas-
sively sensitized by overnight incubation with DNP specific mono-
clonal IgE (SPE7, a gift of Dr. Z. Eshhar, the Weizmann Institute
of Science, Rehovot, Israel), washed three times in Tyrode’s
buffer, and then stimulated with the indicated concentrations of
the antigen, DNP-BSA. Activity of the released 
 
b
 
-hexosaminidase
was determined by incubating aliquots (20 
 
m
 
l) of supernatants and
cell lysates for 90 min at 37
 
8
 
C with 50 
 
m
 
l of the substrate solution
consisting of 1.3 mg/ml p-nitrophenyl-
 
N
 
-acetyl-b-d-glucosaminide
(Sigma Chemical Co.) in 0.1 M citrate pH 4.5. The reaction was
stopped by the addition of 150 ml of 0.2 M glycine, pH 10.7. OD
was read at 405 nm, in an ELISA reader. Results were expressed
as percentage of total b-hexosaminidase activity present in the
cells. To assay the release of cathepsin D, supernatants of cells,
stimulated as above, were concentrated in VivaSpin concentrators
with a 10 kD cut-off (VivaScience, UK). The concentrates were
mixed with 53 Laemmli sample buffer, boiled for 5 min, and
subjected to SDS-PAGE and immunoblotting with anti–cathepsin
D antibodies. For measurement of serotonin release, cells were in-
cubated overnight with 2 mCi of [3H]5-hydroxytryptamine (NEN),
washed, and stimulated as above. Aliquots from the supernatants
were taken for measurement of radioactivity.
SDS-PAGE and Immunoblotting. Samples (normalized accord-
ing to protein content or number of cells) were separated by
SDS-PAGE using 10 or 12% polyacrylamide gels. They were
then electrophoretically transferred to nitrocellulose filters. Blots
were blocked for 3 h in TBST (10 mM Tris-HCl, pH 8.0, 150 mM
NaCl, and 0.05% Tween 20) containing 5% skim milk followed
by overnight incubation at 48C with the indicated primary anti-
bodies. Blots were washed three times and incubated for 1 h at
room temperature with the secondary antibody (horseradish per-
oxidase–conjugated goat anti–rabbit or anti–mouse IgG; Jackson
Research Labs.). Immunoreactive bands were visualized by the
enhanced chemiluminescence method according to standard pro-
cedures.
Cell Transfection. A full-length rat Syt II cDNA (provided by
Dr. T.C. Sudhof) was subcloned into the EcoRI site of the
pcDNA3 expression vector (Invitrogen) both in the sense and
antisense orientations. RBL-2H3 cells (8 3 106) were transfected
with 20 mg DNA of pcDNA3-Syt II or pcDNA3 alone, by elec-
troporation (0.25 V, 960 mF). Cells were immediately replated in
tissue culture dishes containing growth medium (supplemented
DMEM). G418 (1 mg/ml) was added 24 h after transfection and
stable transfectants were selected within 14 d.
Results
Expression Analysis of Endogenous Syt Isoforms. Primers
were chosen from the conserved C2 domains (Fig. 1 A)
that averaged 91% identity with known Syt isoforms. An
initial round of PCR with four different primer pairs did
not yield any visible product in reactions containing RBL
cell cDNA, even though abundant product was obtained
from brain cDNA using two different primer pairs (Fig.
1 B). When the PCR product of RBL cell cDNA with
primers A and D was then used as template in a second
round of PCR, the nested reaction with primers B and C
yielded abundant product of the predicted size of 365 bp
(Fig. 1 C). Sequencing the inserts of 21 colonies of sub-
cloned PCR product yielded 10 colonies encoding a frag-
ment of Syt II, 9 colonies encoding Syt III, and 2 colonies
encoding Syt V. These findings were supported by the re-
sults of restriction digestions of the PCR product with
multiple frequent cutting enzymes (data not shown) that
were consistent with the presence of these three isoforms
and did not indicate the presence of additional isoforms
based on the known sequences of Syt isoforms.
RNase protection assays were then performed to quanti-
tatively assess the expression of Syt isoforms in RBL cells.
Syt II was the most abundant (Fig. 2), and serial dilution of
mRNA used to protect the Syt II probe indicated that this
isoform was approximately fivefold more concentrated in
RBL cells than in Syt III. The Syt V isoform was not pro-
tected even when mRNA was present at a level at least 10-
fold higher than that which measurably protected the Syt II
probe (Fig. 2), suggesting that Syt V mRNA is present in
RBL cells at a concentration less than one-tenth the level
of Syt II.
Because Syt II, which shares the highest homology with
the predominant neural isoform Syt I (31), was the most
abundant isoform, we chose to focus this study on Syt II.
We next examined the expression of the Syt II protein us-
ing specific antibodies (mAb 8G2B, directed against the
NH2 terminus of Syt II). A single immunoreactive protein
was detected in RBL cells (Fig. 3, lane 2). Immunoreactiv-
ity in RBL cells (Mr z80 kD) had less mobility on SDS-
PAGE than immunoreactivity in the brain (Fig. 3, lane 1).
Figure 1. PCR amplification of Syt isoforms. (A) Schematic portrayal
of a representative Syt protein and the four primers for the PCR reac-
tions. (B) An agarose gel of electrophoretically separated products of an
initial round of PCR performed as described in Materials and Methods,
then stained with ethidium bromide. Primer pairs and the source of
cDNA for each reaction are shown above the gel, and size markers are
shown on the right side. (C) An agarose gel of the products of a second
round of PCR, using for a template of the PCR product of RBL cell
cDNA with primers A and D. Primer pairs for the second-round reac-
tions are shown above the gel, and size markers are shown on both sides.1652 Synaptotagmin II Negatively Regulates Mast Cell Lysosomal Exocytosis
Nevertheless, an 80-kD Syt II–immunoreactive protein
was also detected in lysates from fully differentiated, con-
nective tissue–type, RPMCs (Fig. 3, lane 3) and primary
murine BMMCs (Fig. 3, lane 4). These size differences in
Syt II may thus arise from tissue-specific posttranslational
modifications.
Effect of Syt II Overexpression on Ca21-induced Exocytosis.
To study the functional role of Syt II, we stably transfected
RBL cells with neural Syt II cDNA and selected clones
with increased levels (approximately twofold) of Syt II ex-
pression (Syt II1; Fig. 4, lanes 1–3) for further studies. No-
tably, transfection with neural Syt II cDNA resulted in
overexpression of the same 80-kD Syt II–immunoreactive
protein, strengthening the concept that the increased ap-
parent Mr of RBL-Syt II was due to tissue-specific post-
translational modifications.
Overexpression of Syt II had no effect on the spontane-
ous release of the SG-associated enzyme, b-hexosaminidase
(32). In the absence of any stimulus, both control cells
(empty vector-transfected) and cells overexpressing Syt II
released up to 5% of their total b-hexosaminidase (Fig. 5 A).
However, in contrast to transfection with Syt I (27), over-
expression of Syt II failed to potentiate Ca21-dependent
exocytosis evoked by a Ca21 ionophore alone (Fig. 5 A), or
in the presence of phorbol ester (Fig. 5 B). Instead, a mild
inhibition could be observed when the cells were triggered
with low (,10  mM) concentrations of the Ca21 iono-
phore.
Effect of the Suppression of Syt II Expression on Ca21-induced
Exocytosis. The fact that Syt II, unlike Syt I, is endoge-
nously expressed in RBL cells enabled us to extend these
results by investigating the effect of reducing the level of
Syt II expression on exocytosis. To this end, cells were sta-
bly transfected with Syt II cDNA subcloned in the anti-
sense orientation, resulting in substantially reduced levels of
Syt II expression (15, 6, 47, and 6% of control levels) (Fig.
6). Clones expressing the lowest levels (6–15%) were cho-
sen for further analyses. In these cells (Syt II2), the basal,
spontaneous release of b-hexosaminidase was not affected,
revealing that Syt II was not acting as a limiting fusion
clamp. However, b-hexosaminidase release triggered by a
Ca21 ionophore alone (Fig. 5 A) or with phorbol ester
(Fig. 5 B) was markedly (by up to fivefold) potentiated.
The Role of Syt II in FceRI-induced Exocytosis. Physiolog-
ically, exocytosis in mast cells can be triggered by antigen-
induced aggregation of the high-affinity receptors (FceRI) for
IgE (33). To investigate the involvement of Syt II in control-
ling FceRI-mediated exocytosis, antigen-induced secretion
was studied in the Syt II2 and Syt II1 cells. Secretion of
b-hexosaminidase was unaffected in the Syt II1 cells but was
significantly elevated (by fourfold) in the Syt II2 cells (Fig.
7). Taken together, these results suggest that Syt II negatively
regulates release of b-hexosaminidase, whether triggered by
Ca21 ionophore or by an immunological trigger.
Subcellular Distribution of Syt II in RBL Cells. To under-
stand the opposite effects exerted by the transfected Syt I
and Syt II proteins, we investigated their distribution in RBL
cells using a continuous sucrose gradient. All of the Syt II
immunoreactivity present in either the control or the Syt II–
transfected cells comigrated with 60% of the b-hexosamini-
dase activity, present in fractions 6–13 at z0.75 M sucrose
(Fig. 8, A, B, E, and F). These fractions did not include the
histamine-containing SGs, which migrated at fractions 16–23
at 1.3 M sucrose and included the remaining b-hexosamini-
dase activity (Fig. 8, E and F). Histamine was also found at
the top of the gradient (Fig. 8 E), but this probably re-
flected the contents of SGs that were released during cell
disruption. Therefore, these results indicate that, unlike
transfected Syt I (Fig. 8 C), the endogenous and transfected
Syt II proteins were not targeted to the histamine-contain-
ing SGs, but to a different intracellular compartment.
The presence of b-hexosaminidase in fractions 6–13 of the
sucrose gradient suggested the presence of a lysosomal or-
ganelle distinct from the histamine-containing SGs. Indeed,
fractions 6–13 also contained procathepsin D, Mr 53 kD, the
precursor of the lysosomal protease cathepsin D (Fig. 8 D).
Figure 2. RNase protection assay of RBL cell transcripts. Autoradio-
gram of the products of an RNase protection assay after PAGE. The ribo-
probes used for hybridization are listed in the top row, the amount of
mRNA loaded in each lane is listed in the second row, and a size marker
is shown on the left side. This figure is a representative example of an ex-
periment that was repeated four times.
Figure 3. Expression of Syt II
protein in mast cells. Whole lysates
(106 cell equivalents) derived from
RBL-2H3 cells (lane 2), RPMCs
(lane 3), BMMCs (lane 4), and a
crude brain homogenate (lane 1,
10 mg protein), were resolved by
SDS-PAGE and immunoblotted
using the mAb 8G2B directed
against the NH2 terminus of Syt II.
Figure 4. Overexpression of
Syt II in RBL cells. Whole lysates
derived from G418-resistant RBL
clones (1.5 3 106 cell equiva-
lents), transfected with either the
pcDNA3-Syt II recombinant vector (Syt II1, lanes 1–3) or with the empty
pcDNA3 vector (control, lanes 4–6) were resolved by SDS-PAGE and
immunoblotted using monoclonal 8G2B anti–Syt II antibodies.1653 Baram et al.
Effects of Syt II on the Release of Cathepsin D. Lysosomes
were recently shown to behave as Ca21-regulated exocytic
vesicles (34). Since b-hexosaminidase is distributed between
histamine-containing SGs and procathepsin D–containing
lysosomes in RBL cells, it was important to determine
whether secretion of the content of the latter compartment
is negatively regulated by Syt II. To address this question,
we examined whether Syt II could modulate release of the
lysosomally processed form of cathepsin D (mature cathep-
sin D, Mr z43 kD) (35). Concentrating the cell superna-
tants by 20-fold allowed the detection of cathepsin D in su-
pernatants from Ca21 ionophore- or antigen-triggered cells
(Fig. 9 A, lanes 1–3). The amount of secreted mature
cathepsin D was significantly inhibited or increased in the
Syt II1 or Syt II2 cells, respectively (Fig. 9). Ca21 iono-
phore was more effective than the immunological stimulus
in the Syt II1 cells, but did not differ significantly in Syt II2
cells. The precursor form of cathepsin D (53 kD) was de-
tected in supernatants of both triggered and nontriggered
cells (data not shown), reflecting the constitutive release of
unprocessed cathepsin D (34). These results demonstrate
that mast cell activation triggers exocytosis of a lysosomal
fraction distinct from histamine-containing SGs, and that
mobilization of this compartment depends substantially on
the expression level of Syt II.
Effects of Syt II on the Release of Serotonin. We have also
evaluated the effects of Syt II on the triggered release of sero-
tonin, to exclusively monitor exocytosis of SGs (36). Over-
expression of Syt II had no significant effect on serotonin
release triggered by either secretagogue (Fig. 10, A–C).
However, reducing its level of expression in the Syt II2 cells
had a small but significant stimulatory effect (Fig. 10, A–C).
Discussion
Previous studies have already alluded to the possibility
that Syt isoforms may serve the role of general Ca21 sen-
sors, controlling regulated exocytosis also in nonneuronal
Figure 5. Modulation of exocy-
tosis by Syt II. Control (s), Syt II1
(d), and Syt II2 (j) cells were in-
cubated for 30 min at 378C with
the indicated concentrations of
the Ca21 ionophore A23187,
alone (A) or together with 50 nM
TPA (B). The extent of release is
presented as percentage of total
b-hexosaminidase activity. The re-
sults presented in A are from one
experiment, which included sin-
gle clones stably transfected with
the empty pcDNA3 vector, the
pcDNA3–Syt II recombinant vec-
tor, or the pcDNA3–Syt II recom-
binant vector in the antisense ori-
entation. Similar results were
obtained on five occasions and us-
ing two additional clones. The data points presented in B are means 6 SEM of four determinations and include two independent clones stably transfected with
the empty pcDNA3 vector, one clone stably transfected with the pcDNA3-Syt II recombinant vector, and two independent clones stably transfected with
pcDNA3-Syt II in the antisense orientation. Similar results were obtained on five occasions. Inset: b-hexosaminidase release of individual clones (1–3 stably
transfected with the empty pcDNA3 vector and 4–6 stably transfected with pcDNA3-Syt II in the antisense orientation) at a representative concentration of
agonist: A, 10 mM A23187; B, 1 mM A23187 and 50 nM TPA.
Figure 6. Suppression of Syt
II expression. Whole lysates
derived from G418-resistant
RBL clones (1.5 3 106 cell
equivalents), transfected with
either the pcDNA3-Syt II antisense orientation (Syt II2, lanes 1–4) or
with the empty pcDNA3 vector (control, lanes 5–7) were resolved by
SDS-PAGE and immunoblotted as in Fig. 3.
Figure 7. Modulation of FceRI-dependent release by Syt II. Passively
sensitized control (s), Syt II1 (d), and Syt II2 (j) cells were incubated
for 30 min at 378C with the indicated concentrations of the correspond-
ing antigen, DNP-BSA. The extent of release is presented as percentage
of total b-hexosaminidase activity. The results presented are of a repre-
sentative experiment, that included three independent clones, stably
transfected with the empty pcDNA3 vector, three independent clones
stably transfected with the pcDNA3-Syt II recombinant vector and three
independent clones stably transfected with pcDNA3-Syt II in the anti-
sense orientation. The data points are means 6 SEM of six determina-
tions. Similar results were obtained on five occasions. Inset: b-hex-
osaminidase release of individual clones (1–3 stably transfected with the
empty pcDNA3 vector and 4–6 stably transfected with pcDNA3-Syt II in
the antisense orientation) at a representative concentration of antigen (10
ng/ml DNP-BSA).1654 Synaptotagmin II Negatively Regulates Mast Cell Lysosomal Exocytosis
secretory cells (23, 25, 26). We and others have previously
shown that mast cells express Syt and SNAREs that proba-
bly function to control mediators released from these cells
(27, 37). Here, we demonstrate that RBL cells endog-
enously express at least three distinct isoforms of Syt, in-
cluding Syt II, III, and V. Syt II was identified both by
RNAase protection assays (Fig. 2) and at the protein level,
on the basis of its immunoreactivity with specific antibodies
(Fig. 3). However, in contrast to its location on SVs or SGs
in neurons or endocrine cells, in the RBL cells, Syt II co-
fractionates with the lysosomal fraction rather than with the
histamine-containing SGs (Fig. 8). Furthermore, transfec-
tion of the RBL cells with neural Syt II cDNA resulted in
overexpression of Syt II (Fig. 4) and its targeting to the
same fraction (Fig. 8).
Mast cells belong to immune cells of the hemopoietic lin-
eage, where an intimate connection exists between lysosomes
and SGs (38). The SGs of mast cells include, in addition to
their secretory cargo of vasoactive amines (e.g., histamine and
serotonin), lysosomal enzymes such as b-hexosaminidase,
b-glucuronidase, arylsulfatase, and carboxypeptidases (32),
as well as lysosomal integral membrane proteins (LIMPs)
(39). Therefore, mast cell SGs can be defined as secretory
lysosomes. Nevertheless, in consistence with previous data
(40, 41), our data indicate that in addition to the lysosomal,
amine-containing SGs, mast cells also contain lysosomes,
which lack biogenic amines and with which Syt II is associ-
ated (Fig. 8). Such amine-free lysosomes were previously
reported to resist cell triggering by immunologic or Ca21
ionophore stimulation (40, 41). Whether the two popula-
Figure 8. Subcellular fractionation of con-
trol and Syt II–transfected RBL cell lysates.
Fractions from a continuous sucrose gradi-
ent were collected from the top, and assayed
for: A, Syt II immunoreactivity in control
cells; B, Syt II immunoreactivity in Syt II1
cells; C, Syt I immunoreactivity in Syt I1 cells;
D, pro-cathepsin D immunoreactivity; E,
b-hexosaminidase activity (presented as OD
read at 405 nm) (j); histamine content (h)
and LDH activity (d); (F) protein (d) and
sucrose density (s). The data presented in
panels E and F is the average of three
sucrose gradients performed on control, Syt
II1, and Syt I1 cells.1655 Baram et al.
tions of granules are sequentially formed and by what
mechanism selective retention of the nonsecretory lyso-
somes is achieved, remained unknown. We now demonstrate
that mast cells can, to some extent, release also their lysoso-
mal pool of hydrolases, upon both an immunologic and a
Ca21 ionophore trigger. In this process both lysosomal en-
zymes, which are distributed between both SGs and lyso-
somes, such as b-hexosaminidase, as well as hydrolases local-
ized exclusively to the amine-free lysosomal fraction, such as
cathepsin D (Fig. 9), are released. However, this release is
inhibited by overexpression of Syt II and markedly potenti-
ated by reducing the level of Syt II expression (Fig. 9). Re-
cently, three types of granules were ultrastructurally distin-
guished in IFN-g–treated mast cells (Table I). Type I and
type II granules were both labeled by a fluid phase en-
docytic marker and both contained MHC class II as well as
lysosomal markers (42). These results have therefore sug-
gested their position in the endocytic pathway, similarly to
lysosomal compartments (42). Serotonin was localized to
type II and type III granules, of which the latter type did
not internalize the fluid phase endocytic marker, nor did it
contain MHC class II (42). Based on these results, it was
suggested that a fusion event between type I (amine-free
lysosomes) and III (e.g., SGs) granules may account for the
formation of type II granules (42). Our results are compati-
ble with this model and define Syt II as the molecular en-
tity, which may control this fusion event and effect selec-
tive retention of the nonsecretory lysosomes during cell
activation (see model shown in Fig. 11). Furthermore, this
model predicts that downregulation of Syt II should also
indirectly affect SG exocytosis by facilitating the fusion
event between the amine-free lysosomes and SGs. Indeed,
we found that suppression of Syt II level of expression also
moderately potentiates serotonin release (Fig. 10).
The molecular mechanism by which Syt II inhibits lyso-
some exocytosis is currently unknown. Syts fall into three
distinct classes that for syntaxin binding require either high
Ca21 concentrations (200 mM) (class A) or low Ca21 con-
centrations (,1 mM) (class B), or do not bind syntaxin in a
Figure 9. Release of Cathepsin D. (A) Control RBL cells (lanes 1–3),
Syt II1 cells (lanes 4–6), and Syt II2 cells (lanes 7–9) were incubated for
30 min at 378C with buffer (lanes 1, 4, and 7), 50 ng/ml of the DNP-
BSA antigen (lanes 2, 5, and 8), or 10 mM of the Ca21 ionophore A23187
(lanes 3, 6, and 9). The concentrated cell supernatants were resolved by
SDS-PAGE and immunoblotted using anti–cathepsin D (Cat D) antibod-
ies. (B) The intensity of the band corresponding to mature cathepsin D
was quantitated by densitometry (using a B.I.S. 202D densitometer,
Dinco & Rhenium, Israel) and is presented as fold stimulation of the level
in control, nonstimulated cells.
Figure 10. Release of serotonin. Control (s), Syt II1 (d) and Syt II2 (j) cells, loaded with [3H]5-hydroxytryptamine (serotonin), were stimulated for
30 min at 378C with the indicated concentrations of the Ca21 ionophore A23187 alone (A), together with 50 nM TPA (B), or with the antigen DNP-
BSA (C). The extent of serotonin release is presented as percentage of the total radioactivity in the cells. The data points presented are means 6 SEM of
8–12 determinations and include three independent clones stably transfected with the empty pcDNA3 vector, three independent clones stably transfected
with the pcDNA3-Syt II recombinant vector, and three independent clones stably transfected with pcDNA3-Syt II in the antisense orientation. Statistical
analysis was performed using two-tailed student’s t test. *P , 0.05; **P , 0.01. Inset: serotonin release of individual clones (1–3 stably transfected with
the empty pcDNA3 vector and 4–6 stably transfected with pcDNA3-Syt II in the antisense orientation) at a representative concentration of agonist: A,
10 mM A23187; B, 1 mM A23187 and 50 nM TPA; and C, 10 ng/ml DNP-BSA.
Table I. Characterization of Mast Cell Granules
Granule type MHC class II b-hexosaminidase Serotonin
I 11 2
II 11 1
III 21 1
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Ca21-dependent manner (class C) (20). Syt II, the major
RBL isoform, and Syt V, the least abundant isoform, are
class A proteins. However, although Ca21 concentrations
measured in neurons during an action potential are high
enough to support Ca21-dependent interaction of class A
Syts with syntaxins, the rise of intracellular Ca21 concentra-
tion in mast cells induced by FceRI cross-linking rarely ex-
ceeds 1 mM and would not be predicted to support such
interaction (43). Calcium-dependent Syts negatively regu-
late neuronal exocytosis at basal Ca21 concentrations (44),
whereas positive effects on exocytosis are observed only at
elevated Ca21 concentrations and are thought to depend on
interaction with syntaxin (20). In the mast cells Syt II seems
to increase the Ca21 requirements for lysosomal exocytosis,
since Ca21 ionophore is far more effective than immuno-
logic stimulation in triggering cathepsin D release from
control cells, but both are equally potent in Syt II2 cells
(Fig. 9). It is of great interest that Syt II appears to be used
in mast cells as a negative regulator of Ca21-dependent
exocytosis and of a subclass of secretory vesicles, and is the
first example to our knowledge. Syt II inhibitory function
appears to be linked to its lysosomal association since Syt I,
although highly homologous to Syt II, potentiated Ca21-
dependent exocytosis of SG when transfected into the RBL
cells, alongside its SG targeting (27). The reasons for this
differential targeting of Syt I and Syt II remain unknown.
Although not proven here, the remaining Syt isoform
expressed in RBL cells, Syt III, which is a class B protein,
would be an adequate candidate to serve as the positive
regulator of SG exocytosis, whose action is mimicked by
transfected Syt I.
In conclusion, our findings provide unequivocal evi-
dence for an active role of Syt II in negatively controlling
Ca21-regulated lysosomal exocytosis. This observation ex-
tends the function of Syt II to regulation of exocytosis of
secretory organelles exclusive to SVs or SGs. Specifically, in
mast cells regulation by Syt II may have important implica-
tions on their function as APCs in host defense mecha-
nisms, as this process requires uptake and lysosomal pro-
cessing of antigens, followed by presentation of MHC class
II–peptide complexes on the mast cell surface (10, 45). Our
model predicts that the cellular level of Syt II could be up-
or downregulated to determine the balance of mast cell ef-
fector function between the secretion of inflammatory me-
diators from SG exocytosis and the presentation of antigen
by externalization of MHC II–containing lysosomes. Syt II
may thus play a central role in controlling the physiological
functions of mast cells.
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